Genzyme Corporation Homepage We have detected that your browser does not have Javascript turned on.
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
Millennium | Media | Press Releases | 2003 | 2003-07-22 2003 2002 Millennium Reports Second Quarter 2003 Financial Results – Reports VELCADE™ (bortezomib) for Injection Sales for First Time – CAMBRIDGE, Mass., July 22, 2003 - Millennium Pharmaceuticals, Inc.Campath ® (alemtuzumab) humanized monoclonal antibody.
Millennium | Media | Press Releases | 2002 | 2002-01-07 2003 2002 Millennium Initiates Combination Oncology Trials of MLN341 with Taxotere® – Furthers aggressive Clinical Development Program of Investigational Compound in Solid Tumors in Conjunction with Chemotherapy Agent – CAMBRIDGE, Mass., January 7, 2002 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2002 | 2002-01-22 2003 2002 Millennium Reports Year End 2001 Financial Results Cambridge, MA, January 22, 2002 - Millennium Pharmaceuticals, Inc.Campath ® (alemtuzumab) humanized monoclonal antibody was cleared for marketing and successfully launched through our joint venture with ILEX in both the U.S and Europe.
Millennium | Media | Press Releases | 2002 | 2002-04-08 2003 2002 Millennium Researchers Announce Preclinical Findings of its Proteasome Inhibitor MLN341 Against Several Solid Tumor Types – Investigational compounds unique mechanism of action may also help overcome resistance to chemotherapy – Cambridge, Mass., April 8, 2002 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2002 | 2002-05-20 2003 2002 Preliminary Phase II Data on Millennium's Proteasome Inhibitor MLN341 Hold Promise for Patients with Multiple Myeloma Cambridge, MA, May 20, 2002 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2002 | 2002-05-21 2003 2002 Millennium Researchers Announce Preliminary Phase I Findings of Proteasome Inhibitor MLN341 Against Several Solid Tumor Types – In combination with other therapies, investigational compound was well tolerated with early evidence of anti-tumor activity – Cambridge, MA, May 21, 2002 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2002 | 2002-06-06 2003 2002 FDA Grants Millennium's MLN341 and MLN518 Fast Track Status – Phase III multiple myeloma and Phase I acute myeloid leukemia (AML) studies treat patients with unmet medical needs – Cambridge, MA, June 6, 2002 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2002 | 2002-07-16 2003 2002 Millennium Reports Second Quarter 2002 Financial Results – Strong INTEGRILIN® (eptifibatide) Injection Sales; Significant Clinical Progress in Oncology Franchise – Cambridge, MA, July 16, 2002 - Millennium Pharmaceuticals, Inc.Campath ® (alemtuzumab) humanized monoclonal antibody...
Millennium | Media | Press Releases | 2002 | 2002-10-20 2003 2002 77 Per Cent of Multiple Myeloma Patients Showed Reduction or Stabilisation in Myeloma (M) Protein Levels in Preliminary Phase II Data for Proteasome Inhibitor Bortezomib – Investigational compound halted disease progression and reduced tumor burden in patients whose condition had progressed after multiple prior therapies – Nice, France, October 20, 2002 -...
Millennium | Media | Press Releases | 2002 | 2002-11-21 2003 2002 Millennium Initiates Phase I Clinical Trial of MLN2704 in Patients with Metastatic Androgen-Independent Prostate Cancer – PSMA targeting monoclonal antibody vehicle attached to chemotherapeutic agent – Cambridge, Mass., November 21, 2002 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2002 | 2002-12-09 2003 2002 New Data from VELCADE™ (bortezomib) for Injection Crest Study Indicate Responses in Patients with Relapsed Multiple Myeloma – Complements SUMMIT study in earlier stage of disease – Philadelphia, Penn., December 9, 2002 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2002 | 2002-12-09 2003 2002 Final Phase II Data Presented from the VELCADE™ (bortezomib) for Injection SUMMIT Trial in Patients with Advanced Stage Multiple Myeloma – 16.4 month median survival reported – Philadelphia, Penn., December 9, 2002 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2002 | 2002-12-30 2003 2002 Millennium Initiates Phase II Clinical Trial with VELCADE™ (bortezomib) for Injection in Patients with Colorectal Cancer – First phase II Company-sponsored trial in solid tumors – Cambridge, Mass., (December 30, 2002) - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2003 | 2003-01-15 2003 2002 Millennium Initiates Phase II Clinical Trial With VELCADE™ (bortezomib) for Injection in Patients with Advanced Non-Small Cell Lung Cancer – Company-sponsored trial will evaluate VELCADE alone and in combination with Taxotere® – Cambridge, Mass., (January 15, 2003) - Millennium Pharmaceuticals, Inc.
Millennium | Media | Press Releases | 2003 | 2003-02-04 2003 2002 Millennium Seeks European Regulatory Approval for Bortezomib (VELCADE™) 3.5MG Powder for Solution for Injection – The Company continues to move forward with rapid, global development – Cambridge, Mass., February 4, 2003 - Millennium Pharmaceuticals, Inc.
Millennium | Media | Business Strategy THE COMPANY'S KEY ALLIANCES, PAST AND PRESENT 2004 GlaxoSmithKline Marketing INTEGRILIN® (eptifibatide) Injection 2003 Johnson & Johnson Marketing VELCADE® (bortezomib) for Injection 2001 Abbott Laboratories 50/50 disease-focused, technology exchange and development Metabolic diseases, technology 2001 Schering-Plough Corporation Marketing INTEGRILIN® (eptifibatide)...
Millennium | Clinicians | Oncology | CAMPATH Overview VELCADE® Campath ® Research and Development Clinical Trials Resources for Patients CAMPATH ® (ALEMTUZUMAB) INJECTION Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
Millennium | Clinicians | Oncology Overview VELCADE® Campath ® Research and Development Clinical Trials Resources for Patients Millennium has a major commitment to the discovery and development of new treatments for cancer, with a sizeable group focused on this area, including cancer biologists, world-leading experts in the field of genomics-based oncology and clinical oncology researchers.
Millennium | Media | Business Partnerships and Alliances THE COMPANY'S KEY ALLIANCES, PAST AND PRESENT 2001 Abbott Laboratories 50/50 disease-focused, technology exchange and development Metabolic diseases, technology 2000 Roche Diagnostics Disease-focused Rheumatoid arthritis diagnostics 2000 Becton Dickinson Disease-focused Colon cancer diagnostics 2000 Aventis Pharma 50/50* disease-focused, technology transfer and technology development...
Millennium | About Millennium | History Millennium was founded in 1993 with a vision that still drives us today:-to transcend the-limits of medicine.
Millennium | Products Millennium Pharmaceuticals currently markets a leading oncology product, VELCADE ® (bortezomib) for Injection.
Inex Pharmaceuticals News Releases-June 21, 2005:-INEX Announces Restructuring Plan and Appoints New President and COO News Release INEX Announces Restructuring Plan and Appoints New President and COO For immediate release: June 21, 2005 Vancouver, BC - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) today announced extensive management changes and a restructuring to conserve cash and to facilitate a new strategic path to advance its lead anticancer drug Marqibo™, its other Targeted...
